Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study
Headache: The Journal of Head and Face Pain,  Clinical Article

Derosier F et al. – This study primarily included subjects whose migraines significantly impacted their lives. Before the study, these subjects used butalbital–containing medications as part of their current migraine treatment regimen and were satisfied with it, suggesting they were butalbital responders who had found a workable treatment strategy for themselves. When treated with SumaRT/Nap versus BCM in this study, however, a significant proportion of subjects reported better treatment outcomes for themselves for both migraine pain and associated symptoms. Use of SumaRT/Nap was also associated with less rescue medication use and a longer time before use of rescue medication compared with both BCM and placebo.

Methods
  • Enrolled subjects were required to have treated at least 1 migraine with a butalbital medication in the past.
  • Enrolled subjects treated 3 moderate to severe migraines using each of the 3 study treatments once in a randomized sequence.
  • The primary endpoint compared SumaRT/Nap versus BCM for sustained pain freedom at 2–24 hours without the use of any rescue medication.
  • This study combines data from 2 identical outpatient, randomized, multicenter, double–blind, double–dummy, 3 attack crossover studies in adult migraineurs (International Classification of Headache Disorders, 2nd edition).

Results
  • A total of 442 subjects treated at least 1 attack with study medication.
  • The majority of the treated subjects were female (88%) with a mean age 43 years, who reported that their migraines had a severe impact on their lives (78% with Headache Impact Test–6 of >59).
  • At screening, 88% of subjects reported current butalbital use; 68% had used butalbital for more than 6 weeks; and 82% reported satisfaction with butalbital.
  • Across treatment groups, 28–29% of subjects took study medication within 15 minutes of migraine onset, 34–37% of subjects took study medication >15 minutes to 2 hours after onset, and 32–36% of subjects took study medication more than 2 hours after onset.
  • This study did not detect a difference at the nominal 0.05 level in percent sustained pain–free between SumaRT/Nap (8%), BCM (6%), and placebo (3%).
  • SumaRT/Nap was superior to BCM for pain free at 2, 4, 6, 8, 24, 48 hours (P ≤ .044); pain relief (mild or no pain) at 2, 4, 6, 8, 24, 48 hours (P ≤ .01); sustained pain relief 2–24 hours (P < .001); migraine free (pain free with no nausea, photophobia, or phonophobia) at 4, 6, 8, 24, 48 hours (P ≤ .046); and complete symptom free (migraine free with no neck/sinus pain) at 4, 6, 8, 48 hours (P ≤ .031).
  • Adverse event incidence was similar for all treatments (10%, 12%, and 9% for placebo, SumaRT/Nap, and BCM, respectively).
  • Nausea was the most frequent adverse event (2%, 2%, and <1% for placebo, SumaRT/Nap, and BCM, respectively).
  • Five serious adverse events were reported by 3 subjects: viral meningitis and colon neoplasm (placebo); chest pain and hypertension 17 days postdose (SumaRT/Nap); and breast cancer (BCM).
  • Investigators judged no serious adverse events related to study medication.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Neurology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Neurology Articles

1 Consumption of nuts and legumes and risk of stroke: a meta-analysis of prospective cohort studies Nutrition, Metabolism & Cardiovascular Diseases, July 28, 2014    Evidence Based Medicine    Clinical Article

2 Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses Canadian Journal of Cardiology, August 7, 2014    Evidence Based Medicine    Review Article    Clinical Article

3 Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin Stroke, August 14, 2014    Clinical Article

4 Supplementation of folic acid and vitamin B12 reduces plasma levels of asymmetric dimethylarginine in patients with acute ischemic stroke Journal of Clinical Neuroscience, August 18, 2014    Clinical Article

5 Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials The Lancet, August 11, 2014    Evidence Based Medicine    Clinical Article

6 Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation Stroke, July 11, 2014    Clinical Article

7 Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab JAMA Neurology, July 18, 2014    Clinical Article

8 Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques Stroke, May 2, 2014    Clinical Article

9 New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach Neuro-Oncology, August 4, 2014    Clinical Article

10 Risk predictors of stroke and mortality following ablation for atrial fibrillation: The California experience 2005-2009 Heart Rhythm, August 1, 2014    Clinical Article

11 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

12 Antiepileptics in migraine prophylaxis: An updated Cochrane review Cephalalgia, August 14, 2014    Clinical Article

13 Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: A double-blind randomized clinical trial Human Psychopharmacology: Clinical and Experimental, July 15, 2014    Clinical Article

14 Medication-overuse headache: a review Full Text Journal of Pain Research, July 2, 2014    Free full text    Review Article

15 Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial The Lancet Oncology, August 26, 2014    Clinical Article

16 Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: A meta-analysis of randomized clinical trials American Journal of Alzheimer's Disease and Other Dementias, July 16, 2014    Clinical Article

17 Reirradiation of recurrent medulloblastoma Cancer, August 1, 2014    Clinical Article

18 Temozolomide after radiotherapy in recurrent low grade diffuse brainstem glioma in adults Journal of Neuro-Oncology, August 21, 2014    Clinical Article

19 Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis Stroke, August 26, 2014    Clinical Article

20 Low testosterone and the risk of dementia in elderly men Alzheimer's & Dementia, July 30, 2014    Clinical Article

Indexed Journals in Neurology: Current Opinion in Neurology, Stroke, Seizure, Cephalgia, Brain Injurymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close